Mindwalk Holdings Corp. · NASDAQ:HYFT
Mindwalk — ImmunoPrecise Antibodies — Q3 2024 Earnings Presentation
14 slides from Mindwalk's earnings presentation, Mar 14, 2024
Slide 1: FY24 Q3 Earnings Presentation
FY24 Q3 Earnings Presentation March 14, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA
Slide 2: Disclosures
Disclosures Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilitie
Slide 3: Fiscal Year 2024 Q3 Business Update
Fiscal Year 2024 Q3 Earnings Call Fiscal Year 2024 Q3 Business Update
Slide 4: Driven by mission and strategy
Fiscal Year 2024 Q3 Earnings Call Driven by mission and strategy Strategic performance growth drivers with vision and focus Core objective over next several years: Innovation Operational Strategic Continue to drive Excellence Development transformation, implementation and execution of mAb research i
Slide 5: Continued performance remains strong
Fiscal Year 2024 Q3 Earnings Call Driven by mission and strategy Continued performance remains strong Performance drivers: strategic focus on sales, customer engagement, and operational efficiencies Q3 2024 Q3 20% YOY increase Q2 2024 $6.2M total revenue 2024 Q1 2024 Q4 2023 Sustained growth: Four b
Slide 6: Steady revenue growth and emerging markets growth
Fiscal Year 2024 Q3 Earnings Call Driven by mission and strategy Steady revenue growth Emerging markets growth Strategic expansion: Utrecht Launch of LENSai BioIntelligence TM and Victoria sites Hub of Suite with the LENSai epitope binning tool Biotherapeutic Notable growth in Oss facility, Intellig
Slide 7: The impact of LENSai Universal Foundation AI Model
The impact of LENSai Universal Foundation AI Model Seamless multi-omics LENSai Powered by HYFTs - Unlimited scalability- data integration Universal AI Foundation Model Flexible, responsive, The great biosphere connector adaptive, innovative customized data Compare products Search Identify Learn Gene
Slide 8: Fiscal Year 2024 Q3 Financial Update
Fiscal Year 2024 Q2 Earnings Call Fiscal Year 2024 Q3 Financial Update
Slide 9: Year to date $18M revenue, 20% growth
Fiscal Year 2024 Q3 Earnings Call Year to date $18M revenue, 20% growth $7.0 M $6.2 M $6.2 M $6.0 M $5.7 M $5.6 M $5.2 M $5.2 M $5.2 M $5.0 M $4.7 M $4.6 M $4.7 M $4.8 M $4.0 M $3.0 M $2.0 M $1.0 M $0.0 M Q1 Q2 Q3 Q4 FY24 FY23 FY22 All values listed in CAD. ir.ipatherapeutics.com | NASDAQ:IPA ©2023
Slide 10: Strategically built for growth
Fiscal Year 2024 Q3 Earnings Call Strategically built for growth Year to date revenue shows on track for record year FY22 BioStrand LENSai acquisition to enable revenue and gross $25 M margin growth rates higher than historical wet lab $21 M $19 M $20 M $17 M $18 M $15 M $14 M $11 M $12 M $11 M $12
Slide 11: Year to date reduction in operating expenses
Fiscal Year 2024 Q3 Earnings Call Year to date reduction in operating expenses R&D spend reflects efficiency of LENSai Universal Foundation AI Model Research & Development Sales & Marketing General & Administrative $14.0 M $13.2 M $3.0 M $12.0 M $12.0 M $11.7 M $2.8 M $2.6 M $2.7 M $11.8 M $10.0 M $
Slide 12: Net Loss of $2.9M, ($0.11) per share
Fiscal Year 2024 Q3 Earnings Call Net Loss of $2.9M, equivalent to ($0.11) per share (basic & diluted) Net Loss Earnings Per Share $0.0 M 0.00 -$1.0 M -0.05 -$2.9 M -0.11 -$2.0 M -$4.7 M -0.10 -0.19 -$3.0 M -0.15 -$4.0 M -$5.0 M -0.20 FY24 Q3 FY23 Q3 FY24 Q3 FY23 Q3 All values listed in CAD. ir.ipat
Slide 13: Unrestricted Cash of $6.2M with reduced cash burn
Fiscal Year 2024 Q3 Earnings Call Unrestricted Cash of $6.2M with reduced cash burn Cash on hand Jan. 31, 2024 cash includes Dec. 2023 equity raise Cash balance reflects strategy to optimize operational efficiencies to fund strategic R&D for building value, and accessing outside capital when the inv
Slide 14: Q&A FY 2024 Q3 Earnings Call
Q&A FY 2024 Q3 Earnings Call The HUB of March 14, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA TSXV: IPA Biotherapeutic ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of ImmunoPrecise Anti
ImmunoPrecise Antibodies — Q3 2024 Earnings Presentation on 6ix